5-methyl-2-(4-methyl-piperazin-1-yl)-3H-pyrimidin-4-one | 57465-73-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 5-methyl-2-(4-methyl-piperazin-1-yl)-3H-pyrimidin-4-one
• 英文别名: 5-methyl-2-(4-methylpiperazin-1-yl)-1H-pyrimidin-6-one
• CAS: 57465-73-3
• 化学式: C₁₀H₁₆N₄O
• 分子量: 208.263
• InChiKey: UUMAJGNSSFKESL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.5
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  47.9
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• Hsp70 modulators and methods for making and using the same
  申请人：Memorial Sloan Kettering Cancer Center

  公开号：US10647683B2

  公开（公告）日：2020-05-12

  The present invention, among other things, provides compounds and compositions thereof for use in the modulation of Hsp70. In some embodiments, the present invention provides a method for inhibiting Hsp70 activity. In some embodiments, the present invention provides a method of treating a subject suffering from or susceptible to a disease, disorder, or condition responsive to Hsp70 inhibition comprising administering to the subject a therapeutically effective amount of a provided compound. In some embodiments, the present invention provides a method for treating or preventing cancer in a subject suffering therefrom, comprising administering to a patient in need thereof a therapeutically effective amount of a provided compound.

  除其他外，本发明提供了用于调节 Hsp70 的化合物及其组合物。在一些实施方案中，本发明提供了一种抑制 Hsp70 活性的方法。在一些实施方案中，本发明提供了一种治疗患有或易患对Hsp70抑制有反应的疾病、紊乱或状况的受试者的方法，包括给受试者施用治疗有效量的所提供的化合物。在一些实施方案中，本发明提供了一种治疗或预防癌症患者的方法，包括向有需要的患者施用治疗有效量的所提供的化合物。
• HSP70 MODULATORS AND METHODS FOR MAKING AND USING THE SAME
  申请人：Memorial Sloan Kettering Cancer Center

  公开号：US20190241526A1

  公开（公告）日：2019-08-08

  The present invention, among other things, provides compounds and compositions thereof for use in the modulation of Hsp70. In some embodiments, the present invention provides a method for inhibiting Hsp70 activity. In some embodiments, the present invention provides a method of treating a subject suffering from or susceptible to a disease, disorder, or condition responsive to Hsp70 inhibition comprising administering to the subject a therapeutically effective amount of a provided compound. In some embodiments, the present invention provides a method for treating or preventing cancer in a subject suffering therefrom, comprising administering to a patient in need thereof a therapeutically effective amount of a provided compound.